The PFKP antibody targets phosphofructokinase-platelet type (PFKP), a key regulatory enzyme in glycolysis. PFKP catalyzes the phosphorylation of fructose-6-phosphate to fructose-1.6-bisphosphate, a rate-limiting step that controls glycolytic flux. As one of three PFK isoforms (PFKM in muscle, PFKL in liver, PFKP in platelets), it is predominantly expressed in platelets, brain, and placenta but also upregulated in various cancers. Dysregulation of PFKP is linked to metabolic reprogramming in tumors, supporting the Warburg effect by enhancing aerobic glycolysis for rapid energy production.
PFKP antibodies are essential tools for studying its expression, localization, and functional roles in physiological and pathological contexts. They enable detection via Western blotting, immunohistochemistry, and immunofluorescence, aiding research on cancer metabolism, neurodegenerative disorders (e.g., Alzheimer’s), and platelet-related diseases. Recent studies also explore PFKP’s non-metabolic roles in regulating autophagy, cell proliferation, and inflammation.
Commercial PFKP antibodies are typically validated for specificity using knockout cell lines or siRNA knockdown. Researchers prioritize antibodies with high affinity and minimal cross-reactivity against PFKL/PFKM isoforms. Understanding PFKP dynamics offers therapeutic insights, as targeting glycolytic enzymes may improve strategies against cancer and metabolic syndromes.